As of 2025-05-20, the Intrinsic Value of BioPharma Credit PLC (BPCR.L) is 1.20 USD. This BPCR.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.88 USD, the upside of BioPharma Credit PLC is 35.50%.
The range of the Intrinsic Value is 1.02 - 1.47 USD
Based on its market price of 0.88 USD and our intrinsic valuation, BioPharma Credit PLC (BPCR.L) is undervalued by 35.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1.02 - 1.47 | 1.20 | 35.5% |
| DCF (Growth 10y) | 1.10 - 1.56 | 1.29 | 45.6% |
| DCF (EBITDA 5y) | 0.75 - 0.97 | 0.81 | -8.9% |
| DCF (EBITDA 10y) | 0.91 - 1.17 | 1.00 | 12.8% |
| Fair Value | 1.19 - 1.19 | 1.19 | 34.41% |
| P/E | 0.84 - 1.40 | 1.08 | 22.2% |
| EV/EBITDA | 0.50 - 1.03 | 0.69 | -22.1% |
| EPV | 0.99 - 1.30 | 1.14 | 29.0% |
| DDM - Stable | 0.47 - 0.95 | 0.71 | -19.6% |
| DDM - Multi | 0.53 - 0.81 | 0.64 | -27.6% |
| Market Cap (mil) | 998.33 |
| Beta | 0.28 |
| Outstanding shares (mil) | 1,129.33 |
| Enterprise Value (mil) | 992.71 |
| Market risk premium | 5.48% |
| Cost of Equity | 13.66% |
| Cost of Debt | 5.00% |
| WACC | 8.86% |